Mukul Agrawal stock jumps 3% after company sets record date for stock split

During Tuesday’s trading session, the shares of one of the leading pharmaceutical companies in India surged 3.7 percent to Rs. 727 on BSE, after the company’s Board announced a record date for the stock split. 

With a market cap of Rs. 1,894 crores, at 03:14 p.m., the shares of Jagsonpal Pharmaceuticals Limited were trading in the green at Rs. 714.3, up by nearly 2 percent, as against its previous closing price of Rs. 700.75. 

What’s the news: 

According to the latest regulatory filings with the stock exchanges, Jagsonpal Pharmaceuticals has fixed the record date on Wednesday, 8th January 2025, for the purpose of a stock split. 

On 23rd October, the company’s Board approved a sub-division/ split of the existing equity shares of the company, such that each Equity Share with a face value of Rs. 5 each will be split into such number of Equity Shares with a face value of Rs. 2 each. 

Future Outlook: 

In FY25, Jagsonpal Pharma recorded revenue growth of more than 20 percent, with operating margins (pre-ESOP) of around 22 percent, and a cash balance restored to levels seen in March 2024. 

Looking ahead, the company aims for revenue growth of 12-14 percent, an improvement in operating margins by 100-150 basis points, and plans to deploy cash for strategic inorganic initiatives. 

Financials: 

The company reported a significant growth in revenue from operations, experiencing a year-on-year increase of nearly 29.3 percent, rising from Rs. 58 crores in Q2 FY24 to Rs. 75 crores in Q2 FY25. 

During the same period, the company’s net profit increased from Rs. 7 crores to Rs. 11 crores, representing an increase of around 57 percent YoY. 

Also read….

Shareholding Pattern: 

As per the September 2024 shareholding pattern, the Promoters hold a 67.98 percent stake in the company, Foreign Institutional Investors (FII) hold a 2.3 percent stake, while Retail Investors and Domestic Institutional Investors (DII) hold a 29.63 percent and 0.11 percent stake in Jagsonpal Pharma, respectively. 

As of September 2024 shareholding pattern data available with the BSE, the ace investor Mukul Mahavir Agrawal holds a 1.75 percent stake in the company. 

Stock Performance: 

The stock has delivered positive returns of nearly 78.5 percent in one year, and around 110.4 percent of multibagger returns in the last six months. So far in 2024, the shares of Jagsonpal Pharmaceuticals have given positive returns of about 80.7 percent. 

About the company: 

Founded in 1978, Jagsonpal Pharmaceuticals Limited, among the top 10 companies in the gynaecology segment, is engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs), with a larger focus on catering to women-specific healthcare needs. 

Written by Shivani Singh 

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Mukul Agrawal stock jumps 3% after company sets record date for stock split appeared first on Trade Brains.